the following Seeking Alpha article was published on 12/1/15 under "Small Cap Solutions, LLC".
www.regenbiopharmainc.com (OTCPK:RGBP)
Regen BioPharma Inc. Attracts Top Researchers to Scientific Advisory Board
SAN DIEGO, December 1, 2015 /PRNewswire/ --
Dr. Harry Lander, President of Regen, expands his role to include serving as Chief Science Officer andrecruits five distinguished scientists to join advisory team
Regen BioPharma, Inc., (RGBP) and (RGBP) today announced that Harry Lander, PhD, currently President of Regen Biopharma, Inc., would also serve as Chief Scientific Officer of the company. Regen also announced that five top researchers have agreed to serve on the company's scientific advisory board. Those researchers are Francesco Marincola, M.D., Ralph Nachman, M.D., Stefano Bertuzzi, Ph.D., Helen Sabzevari, Ph.D. and Lorraine Gudas, Ph.D.
Read More:
finance.yahoo.com/news/regen-biopharma-inc-attracts-top-133000314.html
Regen is optimistic that all concerns presented by the FDA have been addressed and that the FDA will grant clearance to the Company to initiate clinical trials on HemXellerate.
Regen is also developing and performing Pre Clinical Trial for numerous other new drugs for the treatment of : Breast, Liver, Prostate and Kidney Cancer, Leukemia, and Rare Blood Diseases/Disorders.
Regen is a likely candidate to be targeted for Buyout/Merger with a Large Pharma Co. or poised to become the Front Runner in Stem Cell Treatments.
Regen is a LONG PLAY with previously proven Short Term Gain potential of 35 to over 100 %.
